Daily Biotech Movers — 2026-10-13: A 6-to-1 Down Tape in Which the Only Name With Fresh News Had Just Been Recapitalised

Tuesday, October 13, 2026 was the second session in a row of broad, small-cap biotech selling, and it was roughly twice as severe as the first. Across 570 tracked public biotech and life-sciences companies, 561 carried a directional print: 79 finished higher against 482 lower — a 6.10-to-1 decliner-to-advancer ratio, against Monday’s 2.88-to-1 — and only 14.1% of directional names moved up, the narrowest advance ratio in this series. The median move was -3.57% and the mean -3.59%, with a standard deviation of 9.29%. The average advancer gained +4.68%; the average decliner lost -4.95%. 206 names moved at least 5%, and 219 cleared the anomaly filter once volume-only prints are included — the largest anomaly population of the past month. The spread between the best and worst print was 216 percentage points: Alaunos Therapeutics +188.57% at one end and Actuate Therapeutics -27.56% at the other.

The macro backdrop does not explain a decline of this size. The S&P 500 closed -0.01%, effectively unchanged. The small-cap biotech proxy (XBI) fell -3.03% and the broad biotech proxy (IBB) -2.08%, while the broad healthcare proxy (XLV) lost -1.31%. That XLV print separates Tuesday from Monday. On Monday the defensive, revenue-positive healthcare sleeve rose while biotech fell — a clean rotation out of clinical-stage risk into cash-generative assets. On Tuesday healthcare fell too; the XLV-to-XBI gap narrowed to 1.7 points and the selling was no longer a rotation inside healthcare but a withdrawal from it, led by its highest-beta corner. The internal distribution confirms it: of the 18 sector buckets with five or more names, every single one finished negative, from Diagnostics -0.82% (n=30) at the benign end to AI / Machine Learning -6.26% (n=6) and Antibodies -5.92% (n=41) at the other.

What makes the session worth reading closely is not the breadth but the placement of information inside it. Only one of the six data-defined extremes carried a same-day company event, and it was the largest gain on the board. The three largest declines were, in order, a company repricing itself around a share count it has registered but not yet sold, a company breaking below $1.00 on below-average volume with no disclosure at all, and the residual unwind of a public offering priced five days earlier. On Monday the losers carried the news; on Tuesday the failure was that almost nobody carried news at all.

The 6 Classes of Mover Signal

Every anomaly-flagged move falls into one of six classes, and the class is what tells you whether the print is tradeable information or mechanics. On October 13 the distribution was unusually lopsided: one Class 3 event, five mechanical and prior-cycle prints, and a Class 4 backdrop that turned from rotation into broad withdrawal.

Class 1 — Halt-release, reverse-split-adjacent or listing-compliance-driven. The compliance tail is visible throughout Tuesday’s board. Alaunos Therapeutics (+188.57% to $3.03 on 127.31x volume) enters the day from a Nasdaq stockholders’-equity deficiency disclosed in an October 9 filing, but its move is a Class 3 event (below), not this class. Sunshine Biopharma (-21.75% to $0.2363 on 0.41x volume) is operating under a September 15–16 written-consent authorization for a reverse split of up to 1-for-20 — its second such action in a year, after the 1-for-10 split effective June 1 — adopted to defend its minimum-bid compliance. ALX Oncology (-22.25% to $0.9796 on 0.80x volume) closed below $1.00 for the first time in this series, which is precisely the level at which the minimum-bid test becomes the operative fact rather than the science. Two of the three deepest declines on the board are therefore compliance-adjacent names, and the third is a dilution story.

Class 2 — Single-stock clinical, regulatory or commercial event. Tuesday produced no clean instance among the leaderboard. That absence is the session’s most important structural fact: on a day when 482 names fell and 206 moved at least 5%, not one of the six extremes moved because a trial read out, a regulator acted or a drug sold.

Class 3 — Buyout or strategic capital. One clean instance, and it was the day’s outlier: Alaunos Therapeutics closed at $3.03, up 188.57% from $1.05, on 255,089,694 shares — a 127.31x volume ratio — after completing a stock-for-stock acquisition of privately held Velaris Therapeutics and securing a financing package the company says funds operations into 2029. A reverse-merger completion that recapitalises a shell is the highest-conviction signal in the taxonomy, and the tape treated it as such.

Class 4 — Sector rotation. For the first time in this series the rotation ran against healthcare rather than inside it: XBI -3.03% and XLV -1.31% fell together, with S&P 500 flat. Bucket averages were negative across every sample of five names or more — Small Molecule Pharma -4.71% (n=150), Stem Cells/Cellular Therapy -4.81% (n=23), RNA, Peptide & Gene Therapy -5.86% (n=27), Antibodies -5.92% (n=41) — and even the defensive end was red, with Diagnostics -0.82% (n=30), Devices – Surgical -1.69% (n=27) and Generic Drugs -1.95% (n=5). There was no positive sleeve to rotate into. When the largest and most representative bucket in the universe — 150 names of small-molecule pharma — averages -4.71%, what is being sold is the small-cap clinical complex itself, not a handful of stories within it.

Class 5 — Sell-the-news, prior-cycle profit-taking or dilution unwind. The dominant class on the losing side of the board. Actuate Therapeutics (-27.56% on 3.15x volume), Sunshine Biopharma (-21.75% on 0.41x volume), Cadrenal Therapeutics (+14.28% on 2.09x) and Jupiter Neurosciences (+12.00% on 0.90x) are all trading the consequences of disclosures made between October 6 and October 9 — an S-1, an offering pricing, a strategic review and a Phase 2a first-patient dosing — rather than anything printed on Tuesday.

Class 6 — Stealth accumulation or distribution. Three names printed anomalous volume without an anomalous price move: Cellectar Biosciences (-2.80% on 6.98x volume), Intelligent Bio Solutions (-2.63% on 4.66x) and CNS Pharmaceuticals (+0.19% on 3.54x). Each is trading between 3.5x and 7x its trailing average while moving less than 3%, the signature of supply or accumulation being absorbed quietly. On a day this negative, stealth volume on the buy side is worth more attention than the headline prints.

Top 3 Winners — What Drove Them

TCRT — Alaunos Therapeutics — +188.57% on 127.31x volume

Alaunos Therapeutics closed at $3.03, up 188.57% from $1.05, on 255,089,694 shares — a 127.31x volume ratio, the heaviest relative print on the board by a factor of five. The catalyst is same-day, corporate and unambiguous: the company completed its stock-for-stock acquisition of Velaris Therapeutics, a privately held biotech, exchanging Velaris equity for Alaunos common stock plus newly created non-voting Series B and Series C convertible preferred shares in a tax-free reorganisation, accompanied by a financing package management says funds operations into 2029 (MT Newswires via Yahoo Finance, TipRanks, StockTitan). A Form 8-K and a 4:00 a.m. ET press release confirmed the disclosure the same morning, and the five-day print of +32.0% captures the pre-announcement run off the $0.79 level as sellers responding to the October 5 Nasdaq stockholders’-equity notice were absorbed. The mechanism matters more than the percentage: a shell that closed below $0.80 eight sessions ago on delisting arithmetic has been re-based into a company with a funded pipeline and a converted holder base, and 255 million shares — roughly 74 times the prior float — is the cost of that transition being marked in a single session. The equity still sits in the upper half of a $0.72–$4.50 annual range, but the 52-week context is now the wrong frame for it. Class 3 — buyout and strategic capital, clean same-day catalyst.

CVKD — Cadrenal Therapeutics — +14.28% on 2.09x volume

Cadrenal Therapeutics closed at $0.997, up 14.28% from $0.8724, on 379,480 shares — a 2.09x ratio — with the close essentially on the $1.00 line and the five-day print still -7.76%. There is no same-day release and no Tuesday issuer filing beyond a cluster of five Form 4s reporting option grants (transaction code A, $0.91 strike, ten-year term, transaction date October 9) to Chairman and CEO Quang X. Pham and four other officers and directors (SEC EDGAR — Form 4 filings). The operative narrative is the October 7 launch of a formal strategic review, with the company retaining Tungsten Advisors to lead a process covering a sale, out-licensing or other monetisation of its orphan thrombo-inflammatory assets — CAD-1005, tecarfarin, frunexian and CAD-2000 — following July 28 FDA alignment on the CAD-1005 Phase 3 protocol and statistical analysis plan (RTTNews, GlobeNewswire, Fierce Biotech). Against a market capitalisation of roughly $3.3 million on a $0.8163–$14.4999 annual range, a 14% move on 2.1x turnover is float mechanics plus review speculation, not a discrete event: the company is small enough that a few hundred thousand shares of repositioning sets the price. Class 5 — prior-cycle continuation. No clean same-day catalyst — flagged.

JUNS — Jupiter Neurosciences — +12.00% on 0.90x volume

Jupiter Neurosciences closed at $3.36, up 12.00% from $3.00, on 71,449 shares — a 0.90x ratio, i.e. below-average turnover — extending a five-session gain of +25.6%. No same-day release or issuer filing exists beyond a routine Form S-8 registering plan shares. The operative disclosure is the October 6 announcement that the first patient has been dosed in the Phase 2a RESET trial of JOTROL in Parkinson’s disease — a 30-patient, 12-week, randomised, double-blind, placebo-controlled study with biomarker endpoints — paired in the same release with the board’s exploration of strategic options to maximise shareholder value (GlobeNewswire, AInvest, MarketBeat). The 0.90x volume argues against fresh institutional flow, and the 52-week range of $2.251–$135.7839 is still reverse-split-adjusted from the 1-for-75 split effective August 6, 2026 — which means the percentage moves on this chart are amplified by a float that has been shrunk by 98.7%. A company with roughly $4.4 million of market capitalisation and five employees can print double-digit gains on 71,000 shares, and this one did. Class 5 — prior-cycle continuation. No clean same-day catalyst — flagged.

Top 3 Losers — What Drove Them

ACTU — Actuate Therapeutics — -27.56% on 3.15x volume

Actuate Therapeutics closed at $0.4663, down 27.56% from $0.6437, on 968,098 shares — a 3.15x ratio — taking the five-day print to -26.4% and the close to 43% below the assumed offering price. There is no Tuesday filing or release. The driver is the equity overhang created on October 6, when Actuate filed a preliminary S-1 registering 50,000,000 shares of common stock at an assumed $0.819 per share — roughly $41 million of gross proceeds against a company holding about $4 million of cash — followed by an October 8 free-writing prospectus as the deal was marketed (AInvest, Kalkine Media, StockTitan). This is the second and third leg of a slide that began with the registration: the stock closed $0.8116 the day the S-1 was filed and has not recovered a session since. The 3.15x volume says this is distribution rather than drift, and the mechanism is dilution arithmetic on elraglusib — the registration implies a share count several times the current float, so the tape is repricing to a diluted per-share value before the shares are sold. The close sits above the $0.60 low of its $0.60–$8.3037 annual range, which is the only reassuring number in the paragraph. Class 5 — dilution unwind. Prior-cycle catalyst — flagged.

ALXO — ALX Oncology — -22.25% on 0.80x volume

ALX Oncology closed at $0.9796, down 22.25% from $1.26, on 1,002,174 shares — a 0.80x ratio, below average — while the five-day print remains +4.13%. No SEC filing has been made by the company since August 6 (its second-quarter report and 8-K), and no company release or third-party headline dated October 13 explains the move; the most recent published items are the September 2 Nature Medicine publication of ASPEN-06 Phase 2 data in HER2-positive gastric cancer and an October 4 analyst price-target note carrying a $4.60 consensus target (ALX Oncology — news, MarketBeat). The print is notable for what it is not. At 0.80x volume there is no institutional footprint, and the close puts the stock below $1.00 for the first time in this series, against a $1.05–$2.66 annual range — a level that implicates the Nasdaq minimum-bid test rather than any development on evorpacept or ALX2004. Shares recovered +9.6% in after-hours trade, which is itself the tell that a mechanical seller, not an informed one, set the closing print. Class 1 adjacent. No clean same-day catalyst — flagged.

SBFM — Sunshine Biopharma — -21.75% on 0.41x volume

Sunshine Biopharma closed at $0.2363, down 21.75% from $0.302, on 4,816,127 shares — a 0.41x ratio — with the five-day print at -28.1%. The mechanism is a completed equity raise: the company priced a $6.0 million public offering on October 8, with the final 424B4 prospectus and a related 8-K following on October 9 (StockAnalysis, SEC EDGAR — filing history, Sunshine Biopharma). The raw tape shows the supply arriving: 177.9 million shares traded on October 7 and 118.5 million on October 8 against a 30-day average of roughly 11 million, before collapsing to 4.8 million on Tuesday. Today’s decline on 0.41x volume is the residual unwind of that supply, layered on the September 15–16 written-consent authorisation for a reverse split of up to 1-for-20. The one bullish-side data point, and it is not nothing, is a new Schedule 13G filed October 13 indicating a fresh holder taking a position into the weakness. Class 5 — dilution unwind. Prior-cycle catalyst — flagged.

The Cross-Cutting Pattern

The pattern on Tuesday is capital structure, not science — and this time the market priced it in both directions. Look at where the six extremes sit relative to their balance sheets rather than their pipelines. The three deepest declines are all financing mechanics: Actuate registered 50 million shares on October 6 against roughly $4 million of cash, Sunshine Biopharma priced a $6.0 million offering on October 8, and ALX Oncology broke below $1.00 with no disclosure at all. The only name to move more than 20% higher is the one that completed a recapitalisation — Alaunos converting Velaris equity into preferred and securing funding into 2029. Cadrenal’s +14% and Jupiter’s +12% are microcap float mechanics inside strategic-review processes, which is the same theme read from the other side: a company that has put itself up for sale trades on the probability of a deal, not on its data. Four of the six extremes, in other words, are prints about share counts and processes rather than about molecules — and the two clean catalysts on the board (an acquisition and a Phase 2a dosing) belong to the same name.

The second half of the pattern is the rotation, and it changed character between Monday and Tuesday. On Monday, XLV rose +0.68% while XBI fell -1.55%, a 2.2-point spread that read as orderly de-risking into revenue-positive healthcare. On Tuesday XLV fell -1.31% and XBI fell -3.03%: the gap narrowed to 1.7 points, and the absolute direction of both turned down against a flat S&P 500. Every one of the 18 sector buckets with five or more names closed negative, including the defensive end — Diagnostics -0.82%, Devices – Surgical -1.69%, Devices – Miscellaneous -3.28%. That is no longer rotation; it is withdrawal. Two sessions do not make a trend, but the sequence matters: a 2.88-to-1 down day with a -1.79% median followed by a 6.10-to-1 down day with a -3.57% median is an accelerating, not a stabilising, tape, and the fact that the second day’s selling reached the sleeves that were bid on the first says capital is leaving the sector rather than repositioning inside it.

The third element is what the tape did not do. There was no capitulation print: the largest relative volume on the board belonged to the day’s biggest winner, and the two largest declines by percentage came on 0.80x and 0.41x volume — below-average turnover on stocks making new lows. When declines of 20%+ occur on light volume in the same session that 206 names move at least 5%, the mechanism is thinner bids and wider spreads rather than an avalanche of shares changing hands. That distinction matters for what comes next: lightly-traded marks reverse more easily than heavy-volume ones, and the after-hours recovery in ALX Oncology is an early instance of exactly that.

The 5 Data Points That Matter

1. Percentage change versus the sector mean. The centre of the distribution moved sharply down, and the extremes sit far outside it. Alaunos’s +188.57% is 192 points above the -3.57% median while sitting in a bucket — Biologics, -2.43% (n=85) — that fell. Actuate’s -27.56% is 24.0 points below the median and 22.9 points below its own Small Molecule Pharma bucket at -4.71% (n=150). ALX Oncology’s -22.25% is 18.7 points below the median and roughly 20 points below its Antibodies bucket at -5.92% (n=41). Sunshine Biopharma’s -21.75% is 18.2 points below the median in a Generic Drugs bucket at -1.95% (n=5). On the winners’ side, Cadrenal’s +14.28% and Jupiter’s +12.00% are 17.9 and 15.6 points above the median — large in relative terms, small in absolute market value.

2. Volume ratio. This column separates information from mechanics more cleanly than anything else on the page. The day’s two largest percentage declines printed 0.80x and 0.41x of average volume — the signature of a thin bid rather than informed selling — while the largest gain printed 127.31x on 255.1 million shares. The only other genuine volume events on the board are the two names with the week’s offerings: Actuate at 3.15x on 968,098 shares and Sunshine Biopharma’s collapsing-turnover profile after 296 million shares changed hands across October 7–8. The stealth row is the one to watch: Cellectar Biosciences at 6.98x, Intelligent Bio Solutions at 4.66x and CNS Pharmaceuticals at 3.54x all traded 3.5–7x normal while moving less than 3%, which is what quiet accumulation looks like on a down day.

3. Five-day momentum. Tuesday flags four of six extremes as continuations rather than events. Actuate’s -26.4% into -27.56% and Sunshine Biopharma’s -28.1% into -21.75% are dilution-driven slides in which the five-day print is almost the whole story — there is no single-session shock to explain, only a capital raise working through the float. Jupiter’s +25.6% into +12.00% is a continuation of a week-old strategic-options story. Only two prints break the pattern: Alaunos’s +32.0% into +188.57% is an event landing on top of a pre-positioned run, and ALX Oncology’s +4.13% into -22.25% is a shock against a positive five-day trend with no disclosure behind it, which is the clearest mechanical signature on the board.

4. Position in range and absolute price. Five of the six extremes trade under $3.50, and three trade under $1.00 — Alaunos at $3.03 (range $0.719–$4.50), Cadrenal at $0.997 ($0.8163–$14.4999), Jupiter at $3.36 ($2.251–$135.7839 post-split), Actuate at $0.4663 ($0.60–$8.3037), ALX Oncology at $0.9796 ($1.05–$2.66) and Sunshine Biopharma at $0.2363 ($0.2812–$24.30 post-split). ALX Oncology and Sunshine Biopharma both closed at fresh 52-week lows; Actuate is within 22% of its low. The winners are not making highs either — Alaunos is in the upper half of its range only because of one session, and Cadrenal at $0.997 is still below its annual median. What the column shows is a sector where the entire anomaly board is microcap, and where the percentage moves are amplified by prices a few cents wide.

5. Cash and dilution context. This is the organising fact of the session. Actuate registered roughly $41 million of stock against about $4 million of cash — a registration that, if fully sold, multiplies the float — and has traded down five straight sessions since. Sunshine Biopharma just closed a $6.0 million offering into a market capitalisation that was not much larger, on top of an authorised reverse split of up to 1-for-20 and a 1-for-10 split in June. Cadrenal carries roughly $3.3 million of market capitalisation with a $3.0 million private placement completed in August and a cash runway management has guided only into the first quarter of 2027, which is precisely why it has put the assets up for sale. Jupiter has roughly $4.4 million of market capitalisation, five employees and its own strategic-options process. Set against them: Alaunos, the only name that rallied hard, is the only one whose Tuesday disclosure came with money attached — a completed acquisition plus financing into 2029. On a day whose median print was -3.57%, the market paid for recapitalisation and charged for supply.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why — the 219 anomaly-flagged names, the six data-defined extremes, the signal class behind each, and the cross-cutting pattern: a second consecutive broad small-cap biotech drawdown (79 advancers against 482 decliners, median -3.57%, every sector bucket negative, XBI -3.03% and XLV -1.31% against a flat S&P 500) in which the only clean same-day company catalyst was a completed reverse-merger with financing, the three deepest declines were financing and compliance mechanics, and four of six extremes were prior-cycle prints. It does not tell you what happens next: whether Alaunos’ re-based equity holds above the $1.05 level it broke out from or gives back the recapitalisation print; whether Actuate’s registered share count gets sold at or below the $0.819 assumed price and what the resulting float does to a stock already down 26% on the week; whether Sunshine Biopharma implements its authorised split before the bid-price clock runs out; whether Cadrenal’s review produces a transaction and at what value against a $3.3 million market capitalisation; whether Jupiter’s RESET trial enrolment converts a seven-day-old headline into a data event; and whether ALX Oncology finds a bid above $1.00 before the exchange does the arithmetic for it.

The honest limits are four. First, the catalyst investigation covers the six data-defined top movers only. The rest of the anomaly board carries stories that are noted but not investigated here, and several deserve their own note: Scinai Immunotherapeutics +6.03% on 26.27x volume, Intensity Therapeutics +6.61% on 7.46x, Cognition Therapeutics -6.44% on 9.22x, Biomea Fusion -7.35% on 3.88x, Syndax Pharmaceuticals -15.71% on 3.76x, Inovio Pharmaceuticals -9.67% on 3.05x, HCW Biologics -14.86% on 3.03x, Oncolytics Biotech +3.53% on 3.49x, Boundless Bio -4.71% on 3.42x and Adlai Nortye -17.33% on 4.54x. Second, four of the six extremes had no clean same-day company catalyst. Cadrenal, Jupiter, Actuate and Sunshine Biopharma are labelled prior-cycle or dilution-driven rather than assigned narratives they do not have, and ALX Oncology is labelled mechanical outright. Third, sector averages built on small samples are not averages. Generic Drugs at -1.95% (n=5), Cannabis-related at -2.65% (n=5), AI / Machine Learning at -6.26% (n=6) and Genetics & Genomics at -4.04% (n=7) should not be read as sector verdicts. The meaningful reads are the large samples — Small Molecule Pharma -4.71% (n=150), Biologics -2.43% (n=85), Antibodies -5.92% (n=41), Diagnostics -0.82% (n=30) — and they all say the same thing: this was a broad de-rating of clinical-stage exposure in which even the defensive corner fell. Fourth, two sessions cannot distinguish a rotation from a drawdown. Monday’s breadth was 2.88-to-1 negative and Tuesday’s was 6.10-to-1 with a median twice as deep, which is a deceleration in demand rather than a stabilisation; but the sector is entering the small- and mid-cap reporting window of late October and early November, and a handful of good readouts can reverse a breadth signal this fast. Nothing in this dataset resolves that question — only time will.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-10-13 and will change with market conditions, clinical readouts, financing terms and regulatory events. Micro-cap and clinical-stage names can experience rapid reversals; several of the names discussed here trade under $5.00, carry pending capital, listing-compliance or regulatory events, or have reverse splits, offerings and pending mergers outstanding, and readers should review the underlying filings before drawing conclusions about momentum durability.

Generated 2026-10-13 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorisation from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-10-12.